print_label | resize_label

Science of BYDUREON

Select a category or scroll to learn more.

Select a category or scroll to learn more.


GLP-1 Is an Important Incretin Hormone

Key actions of GLP-1 in glucose homeostasis1

GLP-1 works at multiple sites in the body
GLP-1 works at multiple sites in the body


Continuous GLP-1 Exposure Improved Glucose Levels2

  • Small proof-of-concept study showing the effect of continuously infused GLP-1
  • Exenatide was not used in this study
Mean diurnal plasma glucose
Mean diurnal plasma glucose
Mean diurnal plasma glucose

Adapted from Rachman et al, 1997.

The feasibility and efficacy of continuous administration of GLP-1 were assessed in a 24-hour study in which subjects with type 2 diabetes (n = 7) received a continuous intravenous infusion of GLP-1. Blood glucose measurements were obtained hourly and compared to nondiabetic control subjects receiving saline infusion.

  • Patients with type 2 diabetes receiving continuous saline infusion demonstrated higher glucose levels throughout the day and incremental rises in glucose after meals compared to healthy subjects
  • When the same group of diabetic patients received continuous infusion of GLP-1, they showed improvements in glucose levels both at mealtimes and throughout the day

BYDUREON delivers a continuous release of GLP-1 receptor agonist in a once-weekly dose

Microsphere technology
Microsphere technology
Microsphere technology
  • Microsphere technology enables a gradual rise to steady-state levels and once-weekly dosing
  • Following a single dose of BYDUREON, exenatide is released from the microspheres over approximately 10 weeks
    • With weekly dosing, steady-state concentrations were reached between 6 to 7 weeks and maintained thereafter3,4
  • Exenatide was not detectable approximately 10 weeks after discontinuation of therapy


Pharmacodynamic Effects on FPG Over Time

FPG concentrations over time
FPG concentrations over time
FPG concentrations over time

This double-blind, randomized, placebo-controlled, phase 2 study examined the pharmacokinetic, pharmacodynamic, and safety effects of 2 doses of BYDUREON or placebo over 15 weeks in adults with suboptimally controlled type 2 diabetes (N = 45). The primary objectives of this study were to evaluate the safety, tolerability, and pharmacokinetics of BYDUREON. Secondary objectives included the effect of BYDUREON on glycemic control and body weight.4

  • In the BYDUREON 2 mg QW group (n = 15), a mean reduction in FPG of 17 mg/dL was achieved following 2 weeks of therapy, with full effect on FPG observed by 9 weeks
  • Mean FPG reduction of 40 mg/dL achieved at 15 weeks4

 

Impact on A1C.

Clinical Data

Impact on A1C.

Clinical Data

Impact on A1C.

Patient Support

Patient Support

Free resources for your patients on BYDUREON.

Patient Support

Free resources for your patients on BYDUREON.